Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EOS Clear all
Completed Phase 3 Interventional Results available

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

NCT01842607
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Long Beach, California • Newport Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

NCT04053634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
84
States / cities
Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

NCT04046939
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
36
States / cities
Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 18, 2026, 9:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

NCT02707900
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vorinostat, AGS-004
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Effect of Obesity on Eosinophil Recruitment in Human Adipose Tissue

NCT04234295
View directory record Official record
Conditions
Obese, Healthy
Interventions
Fat Tissue Biopsy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 18, 2026, 9:02 AM EDT
Terminated No phase listed Observational

Sinus Augmentation With Dental Implant

NCT00991393
View directory record Official record
Conditions
Maxillary Sinus Bone Loss
Interventions
INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Fullerton, California • Denver, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 18, 2026, 9:02 AM EDT
Terminated Phase 2 Interventional Results available

Eosinophilic Esophagitis Clinical Therapy Comparison Trial

NCT01821898
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Budesonide, Elimination diet
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 18, 2026, 9:02 AM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Not applicable Interventional

Variability in Spinopelvic Parameters Among Patients Undergoing Total Hip Arthroplasty

NCT05212090
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
EOS X-Ray
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 18, 2026, 9:02 AM EDT
Terminated Not applicable Interventional Results available

A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children

NCT01458418
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Montelukast, placebo, 5 mg Montelukast
Drug · Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

NCT00894231
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
levocetirizine (Xyzal), placebo
Drug
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

NCT01238861
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 18, 2026, 9:02 AM EDT
Completed No phase listed Observational

Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis

NCT02775045
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Observation Period
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 18, 2026, 9:02 AM EDT
Completed No phase listed Observational

The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study

NCT02299362
View directory record Official record
Conditions
Early Onset Scoliosis, Congenital Spinal Deformities, Infantile Idiopathic Scoliosis, Neuromuscular Spinal Deformity, Syndromic Spinal Deformity, Thoracic Insufficiency Syndrome
Interventions
Not listed
Lead sponsor
Growing Spine Study Group
Other
Eligibility
1 Day to 18 Years
Enrollment
2,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

NCT04552288
View directory record Official record
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
Interventions
Benralizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

NCT04322708
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Placebo, lirentelimab (AK002)
Other · Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
73
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 18, 2026, 9:02 AM EDT
Recruiting No phase listed Observational

Study of Gastric Motility in Eosinophilic Gastritis

NCT05229432
View directory record Official record
Conditions
Eosinophilic Gastritis, Gastroparesis, Gastric Motility Disorder
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04753697
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 18, 2026, 9:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Esophageal String Test in Eosinophilic Esophagitis

NCT02008903
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Chicago, Illinois • Peoria, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 18, 2026, 9:02 AM EDT
Completed No phase listed Observational

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

NCT01830712
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 18, 2026, 9:02 AM EDT
Completed Not applicable Interventional Results available

The Effect of Salmeterol on Eosinophil (EOS) Function

NCT00214019
View directory record Official record
Conditions
Allergic Asthma
Interventions
salmeterol, Fluticasone, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 18, 2026, 9:02 AM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching Placebo, ICS/LABA
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 9:02 AM EDT
Completed No phase listed Observational

Early-Onset Sepsis an NICHD/CDC Surveillance Study

NCT02410486
View directory record Official record
Conditions
Infant, Newborn, Diseases, Early Onset Neonatal Sepsis, Early-Onset Meningitis
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 18, 2026, 9:02 AM EDT